- Conditions
- Polycystic Ovary Syndrome, Healthy, Anovulation, Hyperandrogenism
- Interventions
- Recombinant Follicle Stimulating Hormone
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 37 Years · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- La Jolla, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–84
of 84
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- Tildacerfont/Placebo
- Drug
- Lead sponsor
- Spruce Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- Crinecerfont
- Drug
- Lead sponsor
- Neurocrine Switzerland GmbH
- Industry
- Eligibility
- 3 Months to 47 Months
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 11
- States / cities
- San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 8 more
- Conditions
- 21-hydroxylase Deficiency
- Interventions
- Hydrocortisone withdrawal
- Procedure
- Lead sponsor
- Maria I. New
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- New York, New York • Dallas, Texas
- Conditions
- Adrenal Hyperplasia, Congenital
- Interventions
- dexamethasone, Hydrocortisone
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 2 Years to 9 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hyperandrogenism
- Interventions
- Dehydroepiandrosterone (DHEA), Placebo
- Dietary Supplement · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- Abiraterone acetate, Placebo, Hydrocortisone, Fludrocortisone
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 2 Years to 9 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more
- Conditions
- Congenital Adrenal Hyperplasia (CAH), Familial Male-Limited Precocious Puberty (FMPP)
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 1 Day to 99 Years
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
- Interventions
- SPI-62 dose
- Drug
- Lead sponsor
- Sparrow Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Columbus, Ohio
- Conditions
- Disorder of Sex Development, Intersex Conditions, Congenital Adrenal Hyperplasia, Hypospadias
- Interventions
- Not listed
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Not listed
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
- Conditions
- Congenital Adrenal Hyperplasia, 21-Hydroxylase Deficiency, Adrenogenital Syndrome
- Interventions
- Chronocort, Cortef
- Drug
- Lead sponsor
- Neurocrine UK Limited
- Industry
- Eligibility
- 16 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Polycystic Ovarian Syndrome (PCOS), Irregular Menstrual Cycles, Androgen Excess
- Interventions
- doxycycline, Sugar Pill
- Drug · Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, New York